Boston Partners Increases Stake in Haemonetics Co. (NYSE:HAE)

Boston Partners increased its position in shares of Haemonetics Co. (NYSE:HAE) by 27.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 536,262 shares of the medical instruments supplier’s stock after buying an additional 115,506 shares during the period. Boston Partners’ holdings in Haemonetics were worth $41,485,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Intech Investment Management LLC increased its stake in shares of Haemonetics by 107.5% during the fourth quarter. Intech Investment Management LLC now owns 46,338 shares of the medical instruments supplier’s stock valued at $3,618,000 after buying an additional 24,009 shares during the period. Thrivent Financial for Lutherans increased its stake in shares of Haemonetics by 14.9% during the fourth quarter. Thrivent Financial for Lutherans now owns 1,264,294 shares of the medical instruments supplier’s stock valued at $98,716,000 after buying an additional 164,111 shares during the period. William Blair Investment Management LLC increased its stake in shares of Haemonetics by 29.6% during the fourth quarter. William Blair Investment Management LLC now owns 446,258 shares of the medical instruments supplier’s stock valued at $34,844,000 after buying an additional 101,807 shares during the period. Cibc World Markets Corp purchased a new position in shares of Haemonetics during the fourth quarter valued at $367,000. Finally, Natixis Advisors LLC purchased a new position in Haemonetics in the fourth quarter valued at about $1,194,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. Raymond James reiterated a “strong-buy” rating and issued a $115.00 target price (down previously from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. Bank of America lowered Haemonetics from a “neutral” rating to an “underperform” rating and cut their target price for the company from $95.00 to $68.00 in a research note on Friday, February 7th. Barrington Research cut their target price on Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. JPMorgan Chase & Co. assumed coverage on Haemonetics in a research note on Friday, December 6th. They issued an “overweight” rating and a $116.00 target price on the stock. Finally, JMP Securities cut their target price on Haemonetics from $125.00 to $100.00 and set a “market outperform” rating on the stock in a research note on Friday, February 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Haemonetics presently has a consensus rating of “Moderate Buy” and an average target price of $101.22.

Haemonetics Trading Up 1.0 %

Haemonetics stock opened at $65.32 on Thursday. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35. Haemonetics Co. has a 52 week low of $58.80 and a 52 week high of $97.97. The company has a market capitalization of $3.28 billion, a price-to-earnings ratio of 25.72, a price-to-earnings-growth ratio of 1.11 and a beta of 0.43. The stock has a 50-day moving average price of $67.82 and a 200 day moving average price of $75.19.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. Sell-side analysts anticipate that Haemonetics Co. will post 4.55 EPS for the current year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.